251 related articles for article (PubMed ID: 15701267)
1. Designing a randomized phase I/II prostate cancer chemoprevention trial using 1alpha-hydroxy-24-ethyl-cholecalciferol, an analogue of vitamin D3.
Packianathan S; Mehta RG; Mehta RR; Hall WH; Boerner PS; Beckett LA; Vijayakumar S
Cancer J; 2004; 10(6):357-67. PubMed ID: 15701267
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials.
Lieberman R
Urology; 2001 Apr; 57(4 Suppl 1):224-9. PubMed ID: 11295633
[TBL] [Abstract][Full Text] [Related]
3. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372
[TBL] [Abstract][Full Text] [Related]
4. Design considerations for efficient prostate cancer chemoprevention trials.
Lee JJ; Lieberman R; Sloan JA; Piantadosi S; Lippman SM
Urology; 2001 Apr; 57(4 Suppl 1):205-12. PubMed ID: 11295629
[TBL] [Abstract][Full Text] [Related]
5. Validation of surrogate endpoint biomarkers in prostate cancer chemoprevention trials.
Trock BJ
Urology; 2001 Apr; 57(4 Suppl 1):241-7. PubMed ID: 11295636
[TBL] [Abstract][Full Text] [Related]
6. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
7. Models for early chemoprevention trials in breast cancer.
Fabian CJ; Kimler BF; Elledge RM; Grizzle WE; Beenken SW; Ward JH
Hematol Oncol Clin North Am; 1998 Oct; 12(5):993-1017. PubMed ID: 9888018
[TBL] [Abstract][Full Text] [Related]
8. Chemoprevention of prostate cancer: concepts and strategies.
Kelloff GJ; Lieberman R; Steele VE; Boone CW; Lubet RA; Kopelovitch L; Malone WA; Crowell JA; Sigman CC
Eur Urol; 1999; 35(5-6):342-50. PubMed ID: 10325487
[TBL] [Abstract][Full Text] [Related]
9. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
[TBL] [Abstract][Full Text] [Related]
10. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
[TBL] [Abstract][Full Text] [Related]
11. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
12. Clinical trial designs for targeted agents.
Ma BB; Britten CD; Siu LL
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1287-305. PubMed ID: 12512393
[TBL] [Abstract][Full Text] [Related]
13. Is There a Future for Chemoprevention of Prostate Cancer?
Bosland MC
Cancer Prev Res (Phila); 2016 Aug; 9(8):642-7. PubMed ID: 27099271
[TBL] [Abstract][Full Text] [Related]
14. SELECT: the selenium and vitamin E cancer prevention trial.
Klein EA; Thompson IM; Lippman SM; Goodman PJ; Albanes D; Taylor PR; Coltman C
Urol Oncol; 2003; 21(1):59-65. PubMed ID: 12684129
[TBL] [Abstract][Full Text] [Related]
15. Bayesian monitoring of phase II trials in cancer chemoprevention.
Cronin KA; Freedman LS; Lieberman R; Weiss HL; Beenken SW; Kelloff GJ
J Clin Epidemiol; 1999 Aug; 52(8):705-11. PubMed ID: 10465313
[TBL] [Abstract][Full Text] [Related]
16. Target populations and strategies for chemoprevention trials of prostate cancer.
Bostwick DG
J Cell Biochem Suppl; 1994; 19():191-6. PubMed ID: 7823591
[TBL] [Abstract][Full Text] [Related]
17. Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5.
Mehta RG; Moriarty RM; Mehta RR; Penmasta R; Lazzaro G; Constantinou A; Guo L
J Natl Cancer Inst; 1997 Feb; 89(3):212-8. PubMed ID: 9017001
[TBL] [Abstract][Full Text] [Related]
18. [Methodological approaches of clinical studies with targeted therapies].
Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
[TBL] [Abstract][Full Text] [Related]
19. Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer.
Kelloff GJ; Lieberman R; Steele VE; Boone CW; Lubet RA; Kopelovich L; Malone WA; Crowell JA; Higley HR; Sigman CC
Urology; 2001 Apr; 57(4 Suppl 1):46-51. PubMed ID: 11295594
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D supplementation for prevention of mortality in adults.
Bjelakovic G; Gluud LL; Nikolova D; Whitfield K; Wetterslev J; Simonetti RG; Bjelakovic M; Gluud C
Cochrane Database Syst Rev; 2014 Jan; (1):CD007470. PubMed ID: 24414552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]